Page 24 - Contract Development News Today

SAN DIEGO and GAINESVILLE, Ga., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensatio...

Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell’s business in the US and EuropeTeam ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a...

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a significant collaboration agreement between Willow Biosciences and...

PolyPeptide Group / Key word: Financing PolyPeptide secures revolving credit facility 02.10.2023 / 07:00 CET/CEST Media Release PolyPeptide secures revolving...

Gisele Deblandre, Cell-Easy's Chief Scientific Officer We're thrilled to welcome Gisele Deblandre as our new Chief Scientific Officer! TOULOUSE, France, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer. Over the years, Cell-Easy has recognized the challenges faced by biotechs in bridging the gap between early-s...

Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to manufacture...

The market ended flat on mixed global cues and continued FII selling. About 1,791 shares advanced, 1,756 declined and 122 remained unchanged

As per Trendlyne data, the average target price of Strides Pharma is Rs 530, which shows a downside of 2% from the current market prices. The consensus recommendation from 3 analysts for the stock is a Buy.

Nifty IT index fell 0.54% on fears of a delayed demand recovery in the US due to higher interest rates. Mphasis, Coforge, Tech Mahindra and Infosys were the top losers. Nifty Bank also declined 0.32%, dragged by Bank of Baroda, PNB and Indian Bank

Yields on US treasury bonds surged to a fresh 16-year peak overnight, tipping off a spike in the dollar index to a 10-month high of 106. Both these factors dampened sentiment for equities